FDA: Draft guidance - Pulmonary Tuberculosis: Developing Drugs for Treatment

The purpose of this guidance is to assist sponsors in the clinical development of drugs for the treatment of pulmonary tuberculosis. Specifically, this guidance addresses the FDA’s current thinking regarding the overall development program and clinical trial designs for drugs to support an indication for the treatment of active pulmonary tuberculos is.